$RTRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Travere Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Travere Therapeutics, Inc.. Get notifications about new insider transactions in Travere Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 18 2021 | RTRX | Travere Therapeuti ... | LYONS GARY A | Director | Option Exercise | A | 18.27 | 9,000 | 164,430 | 9,000 | |
| May 18 2021 | RTRX | Travere Therapeuti ... | LYONS GARY A | Director | Grant | A | 0.00 | 3,000 | 0 | 37,000 | 34 K to 37 K (+8.82 %) |
| May 18 2021 | RTRX | Travere Therapeuti ... | Meckler Jeffrey A | Director | Option Exercise | A | 18.27 | 9,000 | 164,430 | 9,000 | |
| May 18 2021 | RTRX | Travere Therapeuti ... | Meckler Jeffrey A | Director | Grant | A | 0.00 | 3,000 | 0 | 67,000 | 64 K to 67 K (+4.69 %) |
| May 18 2021 | RTRX | Travere Therapeuti ... | Squarer Ron | Director | Option Exercise | A | 18.27 | 9,000 | 164,430 | 9,000 | |
| May 18 2021 | RTRX | Travere Therapeuti ... | Squarer Ron | Director | Grant | A | 0.00 | 3,000 | 0 | 14,875 | 11.9 K to 14.9 K (+25.26 %) |
| May 13 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 19.46 | 1,562 | 30,397 | 31,707 | 33.3 K to 31.7 K (-4.70 %) |
| May 13 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 19.14 | 1,563 | 29,916 | 33,269 | 34.8 K to 33.3 K (-4.49 %) |
| May 13 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 19.46 | 375 | 7,298 | 45,594 | 46 K to 45.6 K (-0.82 %) |
| May 13 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 19.14 | 375 | 7,178 | 45,969 | 46.3 K to 46 K (-0.81 %) |
| May 13 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 19.46 | 2,000 | 38,920 | 28,223 | 30.2 K to 28.2 K (-6.62 %) |
| May 13 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 19.14 | 2,000 | 38,280 | 30,223 | 32.2 K to 30.2 K (-6.21 %) |
| Apr 20 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Option Exercise | M | 16.23 | 10,000 | 162,300 | 140,000 | |
| Apr 20 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 26.23 | 10,000 | 262,300 | 188,940 | 198.9 K to 188.9 K (-5.03 %) |
| Apr 20 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Buy | M | 16.23 | 10,000 | 162,300 | 198,940 | 188.9 K to 198.9 K (+5.29 %) |
| Mar 19 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Option Exercise | M | 16.23 | 10,000 | 162,300 | 150,000 | |
| Mar 19 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 27.56 | 7,727 | 212,956 | 188,940 | 196.7 K to 188.9 K (-3.93 %) |
| Mar 19 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 27.35 | 10,000 | 273,500 | 196,667 | 206.7 K to 196.7 K (-4.84 %) |
| Mar 19 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Buy | M | 16.23 | 10,000 | 162,300 | 206,667 | 196.7 K to 206.7 K (+5.08 %) |
| Feb 09 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 31.58 | 1,125 | 35,528 | 46,344 | 47.5 K to 46.3 K (-2.37 %) |
| Feb 09 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 31.41 | 1,125 | 35,336 | 47,469 | 48.6 K to 47.5 K (-2.32 %) |
| Feb 09 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 31.58 | 2,250 | 71,055 | 32,223 | 34.5 K to 32.2 K (-6.53 %) |
| Feb 09 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 31.41 | 2,250 | 70,673 | 34,473 | 36.7 K to 34.5 K (-6.13 %) |
| Feb 09 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Sell | S | 31.58 | 4,813 | 151,995 | 156,813 | 161.6 K to 156.8 K (-2.98 %) |
| Feb 09 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Sell | S | 31.41 | 4,813 | 151,176 | 161,626 | 166.4 K to 161.6 K (-2.89 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Grant | A | 0.00 | 4,500 | 0 | 48,594 | 44.1 K to 48.6 K (+10.21 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Grant | A | 0.00 | 4,500 | 0 | 48,594 | 44.1 K to 48.6 K (+10.21 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | Heerma Peter | Chief Commercial Of ... | Grant | A | 0.00 | 4,500 | 0 | 61,594 | 57.1 K to 61.6 K (+7.88 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Grant | A | 0.00 | 4,500 | 0 | 42,205 | 37.7 K to 42.2 K (+11.93 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | Heerma Peter | Chief Commercial Of ... | Grant | A | 0.00 | 4,500 | 0 | 61,594 | 57.1 K to 61.6 K (+7.88 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Grant | A | 0.00 | 4,500 | 0 | 36,723 | 32.2 K to 36.7 K (+13.97 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Grant | A | 0.00 | 4,500 | 0 | 42,205 | 37.7 K to 42.2 K (+11.93 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Grant | A | 0.00 | 17,500 | 0 | 166,439 | 148.9 K to 166.4 K (+11.75 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Grant | A | 0.00 | 4,500 | 0 | 36,723 | 32.2 K to 36.7 K (+13.97 %) |
| Feb 05 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Grant | A | 0.00 | 17,500 | 0 | 166,439 | 148.9 K to 166.4 K (+11.75 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | Heerma Peter | Chief Commercial Of ... | Sell | S | 28.91 | 563 | 16,276 | 57,094 | 57.7 K to 57.1 K (-0.98 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | Heerma Peter | Chief Commercial Of ... | Sell | S | 30.75 | 563 | 17,312 | 57,657 | 58.2 K to 57.7 K (-0.97 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 28.91 | 563 | 16,276 | 44,094 | 44.7 K to 44.1 K (-1.26 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 28.91 | 1,250 | 36,138 | 44,657 | 45.9 K to 44.7 K (-2.72 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 28.91 | 1,125 | 32,524 | 37,332 | 38.5 K to 37.3 K (-2.93 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 28.91 | 2,500 | 72,275 | 38,457 | 41 K to 38.5 K (-6.10 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 28.91 | 675 | 19,514 | 37,705 | 38.4 K to 37.7 K (-1.76 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 28.91 | 2,500 | 72,275 | 38,380 | 40.9 K to 38.4 K (-6.12 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 28.91 | 1,125 | 32,524 | 32,223 | 33.3 K to 32.2 K (-3.37 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 28.91 | 2,500 | 72,275 | 33,348 | 35.8 K to 33.3 K (-6.97 %) |
| Feb 03 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Sell | S | 28.91 | 2,406 | 69,557 | 148,939 | 151.3 K to 148.9 K (-1.59 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 30.75 | 563 | 17,312 | 45,907 | 46.5 K to 45.9 K (-1.21 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 30.75 | 1,250 | 38,438 | 46,470 | 47.7 K to 46.5 K (-2.62 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Grant | A | 0.00 | 5,000 | 0 | 47,720 | 42.7 K to 47.7 K (+11.70 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 30.75 | 1,125 | 34,594 | 43,457 | 44.6 K to 43.5 K (-2.52 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 30.75 | 2,500 | 76,875 | 40,957 | 43.5 K to 41 K (-5.75 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Grant | A | 0.00 | 5,000 | 0 | 44,582 | 39.6 K to 44.6 K (+12.63 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 30.75 | 675 | 20,756 | 40,880 | 41.6 K to 40.9 K (-1.62 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 30.75 | 2,500 | 76,875 | 41,555 | 44.1 K to 41.6 K (-5.67 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Grant | A | 0.00 | 5,000 | 0 | 44,055 | 39.1 K to 44.1 K (+12.80 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Sell | S | 30.75 | 2,406 | 73,985 | 151,345 | 153.8 K to 151.3 K (-1.56 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Sell | S | 29.60 | 6,328 | 187,282 | 153,751 | 160.1 K to 153.8 K (-3.95 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Grant | A | 0.00 | 15,000 | 0 | 160,079 | 145.1 K to 160.1 K (+10.34 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 30.75 | 1,125 | 34,594 | 35,848 | 37 K to 35.8 K (-3.04 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 30.75 | 2,500 | 76,875 | 36,973 | 39.5 K to 37 K (-6.33 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Grant | A | 0.00 | 5,000 | 0 | 39,473 | 34.5 K to 39.5 K (+14.50 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Option Exercise | M | 10.09 | 25,000 | 252,250 | 275,000 | |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 30.75 | 25,000 | 768,750 | 196,667 | 221.7 K to 196.7 K (-11.28 %) |
| Feb 02 2021 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Buy | M | 10.09 | 25,000 | 252,250 | 221,667 | 196.7 K to 221.7 K (+12.71 %) |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Option Exercise | A | 26.88 | 57,500 | 1,545,600 | 57,500 | |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Grant | A | 0.00 | 15,000 | 0 | 34,473 | 19.5 K to 34.5 K (+77.03 %) |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Option Exercise | A | 26.88 | 212,600 | 5,714,688 | 212,600 | |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Grant | A | 0.00 | 57,260 | 0 | 145,079 | 87.8 K to 145.1 K (+65.20 %) |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Option Exercise | A | 26.88 | 57,500 | 1,545,600 | 57,500 | |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Grant | A | 0.00 | 15,000 | 0 | 39,582 | 24.6 K to 39.6 K (+61.02 %) |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Option Exercise | A | 26.88 | 57,500 | 1,545,600 | 57,500 | |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | Rosenberg Noah L. | Chief Medical Offic ... | Grant | A | 0.00 | 15,000 | 0 | 42,720 | 27.7 K to 42.7 K (+54.11 %) |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Option Exercise | A | 26.88 | 57,500 | 1,545,600 | 57,500 | |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Grant | A | 0.00 | 15,000 | 0 | 39,055 | 24.1 K to 39.1 K (+62.36 %) |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | Heerma Peter | Chief Commercial Of ... | Option Exercise | A | 26.88 | 57,500 | 1,545,600 | 57,500 | |
| Jan 25 2021 | RTRX | Travere Therapeuti ... | Heerma Peter | Chief Commercial Of ... | Grant | A | 0.00 | 15,000 | 0 | 58,220 | 43.2 K to 58.2 K (+34.71 %) |
| Jan 07 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 27.01 | 688 | 18,583 | 24,055 | 24.7 K to 24.1 K (-2.78 %) |
| Jan 07 2021 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 26.65 | 688 | 18,335 | 24,743 | 25.4 K to 24.7 K (-2.71 %) |
| Jan 07 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Sell | S | 27.01 | 3,438 | 92,860 | 87,819 | 91.3 K to 87.8 K (-3.77 %) |
| Jan 07 2021 | RTRX | Travere Therapeuti ... | Dube Eric M | Chief Executive Off ... | Sell | S | 26.65 | 3,438 | 91,623 | 91,257 | 94.7 K to 91.3 K (-3.63 %) |
| Dec 16 2020 | RTRX | Travere Therapeuti ... | ASELAGE STEVE | Director | Sell | S | 26.02 | 5,549 | 144,385 | 196,667 | 202.2 K to 196.7 K (-2.74 %) |
| Nov 17 2020 | RTRX | Travere Therapeuti ... | Clague Laura | Chief Financial Off ... | Sell | S | 23.98 | 7,500 | 179,813 | 19,473 | 27 K to 19.5 K (-27.81 %) |
| Nov 17 2020 | RTRX | Travere Therapeuti ... | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 23.96 | 2,500 | 59,900 | 24,086 | 26.6 K to 24.1 K (-9.40 %) |
| Nov 17 2020 | RTRX | Travere Therapeuti ... | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 23.98 | 2,500 | 59,950 | 25,431 | 27.9 K to 25.4 K (-8.95 %) |
| Nov 13 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 23.62 | 2,500 | 59,046 | 27,931 | 30.4 K to 27.9 K (-8.22 %) |
| Nov 13 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Grant | A | 0.00 | 5,000 | 0 | 30,431 | 25.4 K to 30.4 K (+19.66 %) |
| Nov 13 2020 | RTRX | Retrophin, Inc. | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 23.62 | 2,500 | 59,056 | 26,586 | 29.1 K to 26.6 K (-8.60 %) |
| Nov 13 2020 | RTRX | Retrophin, Inc. | ROTE WILLIAM E. | Senior Vice Preside ... | Grant | A | 0.00 | 5,000 | 0 | 29,086 | 24.1 K to 29.1 K (+20.76 %) |
| Nov 13 2020 | RTRX | Retrophin, Inc. | Clague Laura | Chief Financial Off ... | Sell | S | 23.61 | 7,500 | 177,071 | 26,973 | 34.5 K to 27 K (-21.76 %) |
| Nov 13 2020 | RTRX | Retrophin, Inc. | Clague Laura | Chief Financial Off ... | Grant | A | 0.00 | 15,000 | 0 | 34,473 | 19.5 K to 34.5 K (+77.03 %) |
| Nov 06 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 23.00 | 20,625 | 474,375 | 213,107 | 233.7 K to 213.1 K (-8.82 %) |
| Nov 06 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 21.26 | 2,500 | 53,150 | 233,732 | 236.2 K to 233.7 K (-1.06 %) |
| Oct 05 2020 | RTRX | Retrophin, Inc. | Heerma Peter | Chief Commercial Of ... | Sell | S | 19.35 | 2,188 | 42,338 | 42,329 | 44.5 K to 42.3 K (-4.91 %) |
| Oct 05 2020 | RTRX | Retrophin, Inc. | Heerma Peter | Chief Commercial Of ... | Sell | S | 18.90 | 2,188 | 41,353 | 44,517 | 46.7 K to 44.5 K (-4.68 %) |
| Sep 23 2020 | RTRX | Retrophin, Inc. | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 18.48 | 1,500 | 27,720 | 24,086 | 25.6 K to 24.1 K (-5.86 %) |
| Sep 23 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 18.48 | 1,500 | 27,720 | 25,431 | 26.9 K to 25.4 K (-5.57 %) |
| Sep 23 2020 | RTRX | Retrophin, Inc. | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 18.48 | 750 | 13,860 | 27,555 | 28.3 K to 27.6 K (-2.65 %) |
| Sep 23 2020 | RTRX | Retrophin, Inc. | Clague Laura | Chief Financial Off ... | Sell | S | 18.48 | 1,500 | 27,720 | 19,473 | 21 K to 19.5 K (-7.15 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 18.59 | 1,500 | 27,885 | 25,586 | 27.1 K to 25.6 K (-5.54 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | ROTE WILLIAM E. | Senior Vice Preside ... | Grant | A | 0.00 | 3,000 | 0 | 27,086 | 24.1 K to 27.1 K (+12.46 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 18.59 | 750 | 13,943 | 28,305 | 29.1 K to 28.3 K (-2.58 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Rosenberg Noah L. | Chief Medical Offic ... | Grant | A | 0.00 | 3,000 | 0 | 29,055 | 26.1 K to 29.1 K (+11.51 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 18.59 | 1,500 | 27,885 | 26,931 | 28.4 K to 26.9 K (-5.28 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Grant | A | 0.00 | 3,000 | 0 | 28,431 | 25.4 K to 28.4 K (+11.80 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Clague Laura | Chief Financial Off ... | Sell | S | 18.59 | 1,500 | 27,885 | 20,973 | 22.5 K to 21 K (-6.67 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Clague Laura | Chief Financial Off ... | Grant | A | 0.00 | 3,000 | 0 | 22,473 | 19.5 K to 22.5 K (+15.41 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Dube Eric M | Chief Executive Off ... | Sell | S | 19.29 | 1,565 | 30,186 | 94,695 | 96.3 K to 94.7 K (-1.63 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Dube Eric M | Chief Executive Off ... | Sell | S | 19.28 | 9,240 | 178,133 | 96,260 | 105.5 K to 96.3 K (-8.76 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Dube Eric M | Chief Executive Off ... | Grant | A | 0.00 | 3,000 | 0 | 105,500 | 102.5 K to 105.5 K (+2.93 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Dube Eric M | Chief Executive Off ... | Grant | A | 0.00 | 25,000 | 0 | 102,500 | 77.5 K to 102.5 K (+32.26 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | ROTE WILLIAM E. | Senior Vice Preside ... | Sell | S | 18.59 | 1,500 | 27,885 | 25,586 | 27.1 K to 25.6 K (-5.54 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | ROTE WILLIAM E. | Senior Vice Preside ... | Grant | A | 0.00 | 3,000 | 0 | 27,086 | 24.1 K to 27.1 K (+12.46 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 18.59 | 750 | 13,943 | 28,305 | 29.1 K to 28.3 K (-2.58 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Rosenberg Noah L. | Chief Medical Offic ... | Grant | A | 0.00 | 3,000 | 0 | 29,055 | 26.1 K to 29.1 K (+11.51 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 18.59 | 1,500 | 27,885 | 26,931 | 28.4 K to 26.9 K (-5.28 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Grant | A | 0.00 | 3,000 | 0 | 28,431 | 25.4 K to 28.4 K (+11.80 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Clague Laura | Chief Financial Off ... | Sell | S | 18.59 | 1,500 | 27,885 | 20,973 | 22.5 K to 21 K (-6.67 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Clague Laura | Chief Financial Off ... | Grant | A | 0.00 | 3,000 | 0 | 22,473 | 19.5 K to 22.5 K (+15.41 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Dube Eric M | Chief Executive Off ... | Sell | S | 19.29 | 1,565 | 30,186 | 94,695 | 96.3 K to 94.7 K (-1.63 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Dube Eric M | Chief Executive Off ... | Sell | S | 19.28 | 9,240 | 178,133 | 96,260 | 105.5 K to 96.3 K (-8.76 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Dube Eric M | Chief Executive Off ... | Grant | A | 0.00 | 3,000 | 0 | 105,500 | 102.5 K to 105.5 K (+2.93 %) |
| Sep 22 2020 | RTRX | Retrophin, Inc. | Dube Eric M | Chief Executive Off ... | Grant | A | 0.00 | 25,000 | 0 | 102,500 | 77.5 K to 102.5 K (+32.26 %) |
| Aug 06 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 19.68 | 2,500 | 49,200 | 236,232 | 238.7 K to 236.2 K (-1.05 %) |
| Jul 30 2020 | RTRX | Retrophin, Inc. | Rosenberg Noah L. | Chief Medical Offic ... | Sell | S | 20.49 | 870 | 17,826 | 26,055 | 26.9 K to 26.1 K (-3.23 %) |
| Jun 29 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 20.00 | 10,000 | 200,000 | 238,732 | 248.7 K to 238.7 K (-4.02 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Grant | A | 0.00 | 3,000 | 0 | 11,875 | 8.9 K to 11.9 K (+33.80 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | Orwin John A | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Orwin John A | Director | Grant | A | 0.00 | 3,000 | 0 | 11,875 | 8.9 K to 11.9 K (+33.80 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | Meckler Jeffrey A | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Meckler Jeffrey A | Director | Grant | A | 0.00 | 3,000 | 0 | 64,000 | 61 K to 64 K (+4.92 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | LYONS GARY A | Director | Grant | A | 0.00 | 3,000 | 0 | 34,000 | 31 K to 34 K (+9.68 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | COUGHLIN TIMOTHY | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | COUGHLIN TIMOTHY | Director | Grant | A | 0.00 | 3,000 | 0 | 32,000 | 29 K to 32 K (+10.34 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | Poole Sandra | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Poole Sandra | Director | Grant | A | 0.00 | 3,000 | 0 | 6,500 | 3.5 K to 6.5 K (+85.71 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Grant | A | 0.00 | 3,000 | 0 | 248,732 | 245.7 K to 248.7 K (+1.22 %) |
| May 19 2020 | RTRX | Retrophin, Inc. | Baynes Roy D. | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Baynes Roy D. | Director | Grant | A | 0.00 | 3,000 | 0 | 14,000 | 11 K to 14 K (+27.27 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 15.09 | 3,062 | 46,206 | 245,732 | 248.8 K to 245.7 K (-1.23 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 15.09 | 3,062 | 46,206 | 245,732 | 248.8 K to 245.7 K (-1.23 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 16.41 | 4,063 | 66,674 | 248,794 | 252.9 K to 248.8 K (-1.61 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 16.41 | 4,063 | 66,674 | 248,794 | 252.9 K to 248.8 K (-1.61 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 17.16 | 1,000 | 17,160 | 252,857 | 253.9 K to 252.9 K (-0.39 %) |
| May 14 2020 | RTRX | Retrophin, Inc. | ASELAGE STEVE | Director | Sell | S | 17.16 | 1,000 | 17,160 | 252,857 | 253.9 K to 252.9 K (-0.39 %) |
| May 13 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 16.98 | 527 | 8,951 | 25,431 | 26 K to 25.4 K (-2.03 %) |
| May 13 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 17.16 | 525 | 9,009 | 25,958 | 26.5 K to 26 K (-1.98 %) |
| May 13 2020 | RTRX | Retrophin, Inc. | REED ELIZABETH E | SVP, GC & Corporate ... | Sell | S | 14.95 | 525 | 7,849 | 26,483 | 27 K to 26.5 K (-1.94 %) |